AI Summary & Key Takeaways
AI InsightThe combination of our high-resolution X-ray crystallographic and docking-based virtual screening results reveal alternative binding pockets that could serve as new targets for therapeutic modulation of FKBP1A function.
📌 3 Key Takeaways
Abstract
Objective: FK506-binding protein 1A (FKBP1A) is a peptidyl-prolyl cis–trans isomerase involved in protein folding, signal transduction, and calcium homeostasis. Despite its well-studied biochemical role, structural insights into its ligand-binding diversity remain limited. This work aims to elucidate the structural features of FKBP1A at high resolution and explore potential ligand interactions through molecular docking across three distinct putative binding pockets. Materials and Methods: The crystal structure of human FKBP1A was determined at 1.05 Å resolution, allowing detailed visualization of side-chain conformations, hydrogen-bonding networks, and solvent organization at atomic resolution. Molecular docking was performed using the FDA-approved compound library from DrugBank with Molegro Virtual Docker. Three potential binding pockets—one at the inter-chain region and two mirroring pockets at Chain A and Chain B—were screened independently. The top-ranked compounds were evaluated based on rerank scores and interaction profiles. Results: The high-resolution structure revealed well-defined active-site geometry and multiple hydration states, supporting the catalytic flexibility of FKBP1A. Docking analyses identified several high-affinity ligands with distinct binding preferences across the three sites. The canonical active site favored classical FKBP inhibitors, while the secondary and interface pockets accommodated chemically diverse compounds forming novel hydrogen-bond and π–π stacking interactions. Conclusion: This study provides an atomic-level view of FKBP1A and expands the understanding of its ligand-binding landscape. The combination of our high-resolution X-ray crystallographic and docking-based virtual screening results reveal alternative binding pockets that could serve as new targets for therapeutic modulation of FKBP1A function.